Susan Galbraith
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Radiomics and Machine Learning in Medical Imaging, Cancer Treatment and Pharmacology, MRI in cancer diagnosis, Computational Drug Discovery Methods
Most-Cited Works
- → Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis(2002)340 cited
- → Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging(2003)325 cited
- → Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results(2003)307 cited
- ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.(2002)
- Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.(2010)
- → Metabolism and Disposition of Dasatinib after Oral Administration to Humans(2008)194 cited
- → Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18(2005)178 cited
- Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.(2001)
- → Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging(2002)144 cited
- → Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies(2009)138 cited